Information Provided By:
Fly News Breaks for April 20, 2015
SGEN
Apr 20, 2015 | 11:20 EDT
Piper Jaffray believes Seattle Genetics' ADCETRIS is likely to gain approval in post-transplant Hodgkin's Lymphoma patients, which the FDA accepted today for priority review. An approval would position the drug for "modest" sales growth, Piper says. The firm keeps an Underweight rating on the stock with a $26 price target over concerns about the drug's safety profile in ultimate front-line therapy.
News For SGEN From the Last 2 Days
There are no results for your query SGEN